Compare ATER & NEUP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ATER | NEUP |
|---|---|---|
| Founded | 2014 | 1996 |
| Country | United States | United States |
| Employees | N/A | 8 |
| Industry | Home Furnishings | |
| Sector | Consumer Discretionary | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.0M | 23.0M |
| IPO Year | 2019 | N/A |
| Metric | ATER | NEUP |
|---|---|---|
| Price | $0.58 | $4.34 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $21.00 |
| AVG Volume (30 Days) | ★ 63.9K | 23.7K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 55.77 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $99,045,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $7.48 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.52 | $3.65 |
| 52 Week High | $3.50 | $21.31 |
| Indicator | ATER | NEUP |
|---|---|---|
| Relative Strength Index (RSI) | 39.48 | 55.39 |
| Support Level | $0.52 | $3.99 |
| Resistance Level | $0.74 | $4.56 |
| Average True Range (ATR) | 0.06 | 0.17 |
| MACD | 0.00 | 0.02 |
| Stochastic Oscillator | 27.59 | 66.08 |
Aterian Inc is a technology-enabled consumer products company. Its product categories include home and kitchen appliances, kitchenware, environmental appliances (dehumidifiers and air conditioners), beauty-related products and, consumer electronics. It has various owned and operates brands, including HomeLabs, Squatty Potty, Healing Solutions, PurSteam, and others. The company generates revenue through the online sales of various consumer products that are sold online.
Neuphoria Therapeutics Inc is a clinical-stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders. The company is advancing its drug candidate, BNC 210, an oral, proprietary, selective negative allosteric modulator of the Alpha7 nicotinic acetylcholine receptor, for the acute treatment of social anxiety disorder and for chronic treatment of post-traumatic stress disorder. The Company operates through a single operating and reportable segment focused on the discovery and development of allosteric ion channel modulators designed to transform the lives of patients suffering from serious central nervous system (CNS) disorders with high unmet medical need.